Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.55% Nasdaq Up0.29%

Acura Pharmaceuticals, Inc. (ACUR)

-NasdaqCM
1.30 0.02(1.56%) Apr 15, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Acura Pharmaceuticals, Inc.
616 N. North Court
Suite 120
Palatine, IL 60067
United States - Map
Phone: 847-705-7709
Fax: 847-705-5399
Website: http://www.acurapharm.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Delivery
Full Time Employees:15

Business Summary 

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company’s products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Acura Pharmaceuticals, Inc.

Corporate Governance 
Acura Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Robert B. Jones , 55
Chief Exec. Officer, Pres and Director
509.00K0.00
Mr. Peter A. Clemens , 61
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
291.00K2.00K
Dr. Albert W. Brzeczko Ph.D., 57
VP of Technical Affairs
332.00K0.00
Mr. J. Bradley Rivet , 60
VP of Marketing
171.00K0.00
Mr. Robert A. Seiser , 50
VP, Treasurer and Corp. Controller
200.00K10.00K
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders